Radiochemotherapy with or without cetuximab for unresectable esophageal cancer: final results of a randomized phase 2 trial (LEOPARD-2)
Dirk Rades(University Hospital Schleswig-Holstein), Markus Moehler(Johannes Gutenberg University Mainz), Tobias Bartscht(Universitäres Kinderwunschzentrum Lübeck), Rainer Fietkau(Friedrich-Alexander-Universität Erlangen-Nürnberg), Sofia Männikkö(Pharmatest (Finland)), Claus Belka(LMU Klinikum), Laila König(Heidelberg University), Heinz Schmidberger(Johannes Gutenberg University Mainz), Annett Maderer(Johannes Gutenberg University Mainz), Steven E. Schild(Mayo Clinic Hospital), Anne L. Kranich, Cordula Petersen(Universität Hamburg), Thomas Kuhnt(Leipzig University), Peter Hunold(University of Lübeck), Jürgen Debus(Heidelberg University), Patrick Spillner(University of Tübingen), Nils Homann(Fraunhofer Project Centre Wolfsburg), Karsten Ridwelski(University Hospital Magdeburg), Kerstin Karcher-Kilian(University of Lübeck)
Cited by 12
Related Papers
FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial
|The Lancet Oncology|2014|1.7k
Adjuvant Nivolumab in Resected Esophageal or Gastroesophageal Junction Cancer
|New England Journal of Medicine|2021|1.7k
Non–Small Cell Lung Cancer, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology
|Journal of the National Comprehensive Cancer Network|2022|1.4k